Table 1.
Patient Characteristics
| Characteristics | All Patients | No Anticoagulation (n = 67) |
Anticoagulation or Antiplatelet (n = 122) |
P |
|---|---|---|---|---|
| Age | 59.9 ± 14.4 | 62.6 ± 13.3 | 54.9 ± 15.1 | 0.0004 |
| Gender | 0.565 | |||
| Women | 71 (37.6) | 27 (40.3) | 44 (36.1) | |
| Men | 118 (62.4) | 40 (59.7) | 78 (63.9) | |
| Tobacco | 0.395 | |||
| No | 98 (51.9) | 35 (52.2) | 63 (51.6) | |
| Past | 70 (37.0) | 22 (32.8) | 48 (39.3) | |
| Active | 21 (11.1) | 10 (14.9) | 11 (9.0) | |
| Comorbidities | ||||
| DM | 123 (65.1) | 34 (50.8) | 89 (73.0) | 0.002 |
| HTN | 157 (83.1) | 49 (73.1) | 108 (88.5) | 0.007 |
| HLD | 108 (57.1) | 24 (35.8) | 84 (68.9) | <0.0001 |
| CHF | 38 (20.1) | 6 (9.0) | 32 (26.2) | 0.005 |
| Renal failure | 63 (33.3) | 17 (25.4) | 46 (37.7) | 0.085 |
| CKD | 81 (42.9) | 19 (28.4) | 62 (50.8) | 0.003 |
| PAD | 38 (20.1) | 14 (20.9) | 24 (19.7) | 0.841 |
| Transplant | 7 (3.7) | 3 (4.5) | 4 (3.3) | 0.700 |
| HCV | 14 (7.4) | 7 (10.5) | 7 (5.7) | 0.237 |
| HIV | 7 (3.7) | 4 (6.0) | 3 (2.5) | 0.247 |
| RA | 10 (5.3) | 2 (2.99) | 8 (6.6) | 0.499 |
| BMI | 31.5 ± 8.4 | 32.0 ± 8.4 | 30.6 ± 8.3 | 0.289 |
| A1c | 6.8 ± 1.9 | 6.9 ± 1.8 | 6.8 ± 1.9 | 0.693 |
| Coagulation Laboratories | ||||
| PT | 14.4 ± 2.3 | 14.4 ± 2.8 | 14.5 ± 2.2 | 0.378 |
| PTT | 32.5 ± 7.6 | 34.5 ± 8.7 | 31.8 ± 7.2 | 0.854 |
| INR | 1.4 ± 2.7 | 1.2 ± 0.3 | 1.6 ± 3.2 | 0.315 |
Age, BMI, A1c, PT, PTT, and INR are reported as the mean ± SD. All other variables are reported as n (percent). PT and INR data available for 90 patients. INR data available for 57 patients.
Significant P values (<0.05) are in bold.
DM = diabetes mellitus; HTN = hypertension; HLD = hyperlipidemia; CHF = congestive heart failure; CKD = chronic kidney disease; HCV = hepatitis C virus; HIV = human immunodeficiency virus; RA = rheumatoid arthritis; A1c = hemoglobin A1c; PT = prothrombin time; PTT = partial thromboplastin time; INR = international normalized ratio.